CFHR4 and hepatocellular carcinoma: CFHR4 has also been identified as one of the hepatocyte subtypes in extrahepatic metastasis of advanced HCC and may serve as a predictive target for resistance to the combination therapy of lenvatinib, FOLFOX, and toripalimab [34].